| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/05/2023 | 96.08% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 390.2% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 2350.98% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 1958.82% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 2350.98% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
What is the target price for GT Biopharma (GTBP)?
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by EF Hutton on January 5, 2023. The analyst firm set a price target for $2.00 expecting GTBP to rise to within 12 months (a possible 96.08% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GT Biopharma (GTBP)?
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by EF Hutton, and GT Biopharma initiated their hold rating.
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.
Is the Analyst Rating GT Biopharma (GTBP) correct?
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a initiated with a price target of $0.00 to $2.00. The current price GT Biopharma (GTBP) is trading at is $1.02, which is within the analyst's predicted range.